Lexeo Therapeutics, Inc.
For the period ended Dec 31, 2025. Filed Mar 30, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 30, 2026
LXEO$3.14+8.7%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Statements of Operations and Comprehensive Loss
(In thousands, except share and per share amounts)
| Year Ended December 31, | ||
|---|---|---|
| 2025 | 2024 | |
| Operating expenses | ||
| Research and development | $63,797 | $74,091 |
| General and administrative | 45,460 | 31,675 |
| Total operating expenses | 109,257 | 105,766 |
| Operating loss | (109,257) | (105,766) |
| Other income and expense | ||
| Gain on long-term investment | 3,390 | - |
| Other expense, net | (18) | (9) |
| Interest expense | (95) | (137) |
| Interest income | 6,130 | 7,556 |
| (Amortization of premium) accretion of discount on investments in U.S. Treasury securities, net | (111) | 23 |
| Total other income and expense | 9,296 | 7,433 |
| Loss from operations before income taxes | (99,961) | (98,333) |
| Income taxes | - | - |
| Net loss | $(99,961) | $(98,333) |
| Other comprehensive gain (loss) | ||
| Net unrealized gain (loss) on investments | 291 | (103) |
| Total other comprehensive gain (loss) | 291 | (103) |
| Comprehensive loss | $(99,670) | $(98,436) |
| Net loss per common share, basic and diluted | $(1.86) | $(3.09) |
| Weighted-average number of shares outstanding used in computation of net loss per common share, basic and diluted | 53,645,323 | 31,787,491 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.